260 related articles for article (PubMed ID: 33610731)
1. Exosome-mediated delivery of RNA and DNA for gene therapy.
Munagala R; Aqil F; Jeyabalan J; Kandimalla R; Wallen M; Tyagi N; Wilcher S; Yan J; Schultz DJ; Spencer W; Gupta RC
Cancer Lett; 2021 May; 505():58-72. PubMed ID: 33610731
[TBL] [Abstract][Full Text] [Related]
2. A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy.
Bao X; Wang W; Wang C; Wang Y; Zhou J; Ding Y; Wang X; Jin Y
Biomaterials; 2014 Sep; 35(29):8450-66. PubMed ID: 24997481
[TBL] [Abstract][Full Text] [Related]
3. Milk exosomes - Natural nanoparticles for siRNA delivery.
Aqil F; Munagala R; Jeyabalan J; Agrawal AK; Kyakulaga AH; Wilcher SA; Gupta RC
Cancer Lett; 2019 May; 449():186-195. PubMed ID: 30771430
[TBL] [Abstract][Full Text] [Related]
4. Small RNA combination therapy for lung cancer.
Xue W; Dahlman JE; Tammela T; Khan OF; Sood S; Dave A; Cai W; Chirino LM; Yang GR; Bronson R; Crowley DG; Sahay G; Schroeder A; Langer R; Anderson DG; Jacks T
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3553-61. PubMed ID: 25114235
[TBL] [Abstract][Full Text] [Related]
5. Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers.
Thapa B; Kc R; Bahniuk M; Schmitke J; Hitt M; Lavasanifar A; Kutsch O; Seol DW; Uludag H
Hum Gene Ther; 2019 Dec; 30(12):1531-1546. PubMed ID: 31547718
[TBL] [Abstract][Full Text] [Related]
6. Generation and testing of clinical-grade exosomes for pancreatic cancer.
Mendt M; Kamerkar S; Sugimoto H; McAndrews KM; Wu CC; Gagea M; Yang S; Blanko EVR; Peng Q; Ma X; Marszalek JR; Maitra A; Yee C; Rezvani K; Shpall E; LeBleu VS; Kalluri R
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669940
[TBL] [Abstract][Full Text] [Related]
7. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.
Mao CQ; Xiong MH; Liu Y; Shen S; Du XJ; Yang XZ; Dou S; Zhang PZ; Wang J
Mol Ther; 2014 May; 22(5):964-73. PubMed ID: 24496383
[TBL] [Abstract][Full Text] [Related]
8. Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles.
Talekar M; Trivedi M; Shah P; Ouyang Q; Oka A; Gandham S; Amiji MM
Mol Ther; 2016 Apr; 24(4):759-69. PubMed ID: 26686386
[TBL] [Abstract][Full Text] [Related]
9. Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer.
Yang T; Fogarty B; LaForge B; Aziz S; Pham T; Lai L; Bai S
AAPS J; 2017 Mar; 19(2):475-486. PubMed ID: 27882487
[TBL] [Abstract][Full Text] [Related]
10. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib.
Sreedurgalakshmi K; Srikar R; Harikrishnan K; Srinivasan L; Rajkumari R
Technol Cancer Res Treat; 2021; 20():15330338211041453. PubMed ID: 34542333
[TBL] [Abstract][Full Text] [Related]
12. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy.
Yang Z; Duan J; Wang J; Liu Q; Shang R; Yang X; Lu P; Xia C; Wang L; Dou K
Int J Nanomedicine; 2018; 13():1851-1865. PubMed ID: 29618926
[TBL] [Abstract][Full Text] [Related]
13. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
Mehta A; Dalle Vedove E; Isert L; Merkel OM
Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
Lang FF; Yung WK; Raju U; Libunao F; Terry NH; Tofilon PJ
J Neurosurg; 1998 Jul; 89(1):125-32. PubMed ID: 9647183
[TBL] [Abstract][Full Text] [Related]
15. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
16. Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA.
Cho WY; Hong SH; Singh B; Islam MA; Lee S; Lee AY; Gankhuyag N; Kim JE; Yu KN; Kim KH; Park YC; Cho CS; Cho MH
Eur J Pharm Biopharm; 2015 Aug; 94():450-62. PubMed ID: 26141346
[TBL] [Abstract][Full Text] [Related]
17. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
18. Exosomes are natural carriers of exogenous siRNA to human cells in vitro.
Shtam TA; Kovalev RA; Varfolomeeva EY; Makarov EM; Kil YV; Filatov MV
Cell Commun Signal; 2013 Nov; 11():88. PubMed ID: 24245560
[TBL] [Abstract][Full Text] [Related]
19. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Lu ZX; Liu LT; Qi XR
Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
[TBL] [Abstract][Full Text] [Related]
20. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells.
Choi SH; Jin SE; Lee MK; Lim SJ; Park JS; Kim BG; Ahn WS; Kim CK
Eur J Pharm Biopharm; 2008 Mar; 68(3):545-54. PubMed ID: 17881199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
